Varian Medical Systems led University of Michigan's robotic-assisted ultrasound device spinout's series C round, which also included Johnson & Johnson Innovation - JJDC.
HistoSonics, a US-based developer of a soundwave-based medical treatment device spinout of University of Michigan, completed a $54m series C round yesterday led by cancer treatment technology provider Varian Medical Systems.
Johnson & Johnson Innovation – JJDC, the corporate venturing arm of medical group Johnson & Johnson, also took part, as did VC firm Lumira Ventures, investment firm Venture Investors, State of Wisconsin Investment Board and private investor Fred Moll.
HistoSonics is developing an autonomous robotics platform that will use pulsed sound waves to destroy and liquify diseased tissue and tumours without harming surrounding tissue. The series C funding will go to further development of its technology platform.
The company’s histotripsy technology was developed by co-founders Charles Cain, Brian Fowlkes, Tim Hall, Zhen Xu and William Roberts, scientists in University of Michigan’s Department of Biomedical Engineering or Department of Urology.
Greg Sorensen, vice-president of strategy and…
